Core Viewpoint - The Chongqing Municipal Drug Administration has announced that Taiji Group Chongqing Tongjun Pavilion Pharmaceutical Co., Ltd. has successfully conducted a compliance audit for its licorice material supplier, Inner Mongolia Saiwai Shuo Mo Traditional Chinese Medicine Co., Ltd., confirming adherence to GAP (Good Agricultural Practices) requirements [2]. Group 1: Compliance Information - The compliance audit was based on the guidelines from the National Medical Products Administration and other relevant authorities regarding the production quality management standards for traditional Chinese medicinal materials [2]. - The audit results indicate that the self-evaluation materials submitted by Taiji Group Chongqing Tongjun Pavilion Pharmaceutical Co., Ltd. meet the necessary requirements for GAP compliance [2]. Group 2: GAP Compliance Details - The audit covered various traditional Chinese medicine products, including "Zhi Gan Cao He Ji" and "Huang Lian Shang Qing Wan," with a specific focus on the licorice material sourced from Inner Mongolia [2]. - The licorice cultivation area is reported to be 3,800 mu, located in the regions of Hangjin Duguaitala Town and Jirigala Tu Town in Inner Mongolia [2].

Core Insights - The eighth "Belt and Road" Traditional Chinese Medicine Development Forum and the third OTC Brand Conference will be held in Hangzhou from November 24 to 26, 2025, focusing on the internationalization of traditional Chinese medicine, brand building, and industrial innovation paths [1] Group 1: Company Overview - China National Pharmaceutical Group (China National Pharmaceutical Tai Chi) is a leading enterprise in the traditional Chinese medicine industry, invited to present at the conference with a speech titled "Tai Chi IP: From Chinese Corporate Symbol to Global Health Symbol" [3] - The company has accumulated significant brand assets, including three century-old enterprises, two time-honored brands, six items of intangible cultural heritage, and 1,317 registered trademarks domestically and internationally [4] Group 2: Brand Development Strategy - The company aims to transform "Tai Chi IP" into a unique global health symbol through a systematic strategy involving brand strategy, culture, recognition, communication, experience, and management [7] - The strategic path includes establishing a differentiated communication matrix for the mother brand, sub-brands, and a "4+1 pipeline" brand to promote a nationwide Tai Chi fashion trend [7] Group 3: International Expansion - As one of the "National Traditional Chinese Medicine Service Export Bases," the company has upgraded from "product export" to "service and model export," with over 30 product specifications entering more than 20 countries and regions, achieving nearly 100 overseas registration numbers and doubling export sales [8] - The company plans to build an international technological innovation system tailored to traditional Chinese medicine, integrating traditional theories and modern clinical efficacy to promote Tai Chi culture globally [8] Group 4: Awards and Recognition - At the conference, the company received multiple honors, with its core products ranking first in various categories of the "2025 Annual Comprehensive Statistics Ranking of Non-Prescription Drug Products" [8] - The company aims to continue promoting high-quality development in the traditional Chinese medicine industry, aspiring for "Tai Chi IP" to become a health symbol connecting tradition with modernity and China with the world [10]